Table 6.

Top 10 issues raised by patients in the US and EU

US	EU
1.Better access to care from physicians knowledgeable in MC disorders and more specialized centers	1.Improved knowledge of all doctors in various disciplines relevant to MC disorders
2.Definitions and criteria for MCAS (clonal and nonclonal variants)	2.ID card for all patients and countries in Europe
3.Curative rather than symptomatic therapy	3.New better therapeutic agents
4.Education and awareness of physicians and health care professionals in recognition of symptoms of MC disorders	4.More specialized centers in various countries in the EU
5.Practice parameters of diagnosis and therapy incorporating commonly available methods	5.Improved knowledge and definition of mediator-associated symptoms
6.Better access to and assistance in obtaining medications	6.More mastocytosis specialists
7.More recognition of gastrointestinal manifestations of MC diseases	7.Improved diagnostic methods
8.Better holistic care plans to address symptoms such as anaphylaxis, fatigue, bone pain, brain fog, pain and neuropsychiatric symptoms	8.More information to patients
9.More research into familial occurrence	9.Further development of existing classifications of MC disorders
10.New treatment options for cutaneous disease, aggressive SM and MCL	10.More information to patients via commonly accessible media

The two reports (EU and US) were prepared independently by using documented material provided by the patients' organizations, and with assistance by 2 faculty members.